How to buy OncoSec Medical Incorporated stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy OncoSec Medical Incorporated stock

Own OncoSec Medical Incorporated stock in just a few minutes.

OncoSec Medical Incorporated is a biotechnology business based in the US. OncoSec Medical Incorporated shares (ONCS) are listed on the NASDAQ and all prices are listed in US Dollars. OncoSec Medical Incorporated employs 42 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in OncoSec Medical Incorporated

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

OncoSec Medical Incorporated share price

Use our graph to track the performance of ONCS stocks over time.

OncoSec Medical Incorporated shares at a glance

Information last updated 2021-04-15.
52-week range$1.49 - $8.16
50-day moving average $5.36
200-day moving average $5.44
Wall St. target price$8.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.93

Buy OncoSec Medical Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy OncoSec Medical Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

OncoSec Medical Incorporated financials

Gross profit TTM $0
Return on assets TTM -61.39%
Return on equity TTM -166.76%
Profit margin 0%
Book value $1.32
Market capitalisation $179.4 million

TTM: trailing 12 months

Shorting OncoSec Medical Incorporated shares

There are currently 413,197 OncoSec Medical Incorporated shares held short by investors – that's known as OncoSec Medical Incorporated's "short interest". This figure is 1.1% down from 417,616 last month.

There are a few different ways that this level of interest in shorting OncoSec Medical Incorporated shares can be evaluated.

OncoSec Medical Incorporated's "short interest ratio" (SIR)

OncoSec Medical Incorporated's "short interest ratio" (SIR) is the quantity of OncoSec Medical Incorporated shares currently shorted divided by the average quantity of OncoSec Medical Incorporated shares traded daily (recently around 212988.1443299). OncoSec Medical Incorporated's SIR currently stands at 1.94. In other words for every 100,000 OncoSec Medical Incorporated shares traded daily on the market, roughly 1940 shares are currently held short.

However OncoSec Medical Incorporated's short interest can also be evaluated against the total number of OncoSec Medical Incorporated shares, or, against the total number of tradable OncoSec Medical Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OncoSec Medical Incorporated's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 OncoSec Medical Incorporated shares in existence, roughly 10 shares are currently held short) or 0.0153% of the tradable shares (for every 100,000 tradable OncoSec Medical Incorporated shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OncoSec Medical Incorporated.

Find out more about how you can short OncoSec Medical Incorporated stock.

OncoSec Medical Incorporated share dividends

We're not expecting OncoSec Medical Incorporated to pay a dividend over the next 12 months.

Have OncoSec Medical Incorporated's shares ever split?

OncoSec Medical Incorporated's shares were split on a 1:10 basis on 20 May 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoSec Medical Incorporated shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for OncoSec Medical Incorporated shares which in turn could have impacted OncoSec Medical Incorporated's share price.

OncoSec Medical Incorporated share price volatility

Over the last 12 months, OncoSec Medical Incorporated's shares have ranged in value from as little as $1.49 up to $8.1598. A popular way to gauge a stock's volatility is its "beta".

ONCS.US volatility(beta: 2.29)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoSec Medical Incorporated's is 2.2907. This would suggest that OncoSec Medical Incorporated's shares are significantly more volatile than the average for this exchange and represent a higher risk.

OncoSec Medical Incorporated overview

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co. , Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site